Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa

Objectives: Quality of life (QOL) data were used to evaluate the effects of self-administered intracavernosal injection of alprostadil for erectile dysfunction, when used for up to 18 months during a 13 country Phase III clinical trial. Methods: The Duke Health Profile was used to measure patients’ physical and psychosocial QOL at baseline, 3, 6, 12 and 18 months. Changes from baseline were measured using paired t -tests, with additional analyses by cause of dysfunction, starting dosage, and prior treatment. Results: Patients displayed significant improvements in mental and social health and self-esteem at six months ( P